The Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) drugs in development market research report provides comprehensive information on the therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) by five companies/universities/institutes. The top development phase for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) is preclinical with four drugs in that stage. The Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline products market are: Constant Therapeutics, Prothelia and Myocea.
The key targets in the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline products market include Laminin Subunit Alpha 2 (Laminin M Chain or Laminin 12 Subunit Alpha or Laminin 2 Subunit Alpha or Laminin 4 Subunit Alpha or Merosin Heavy Chain or LAMA2), and Laminin (LAM).
The key mechanisms of action in the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline product include Laminin Subunit Alpha 2 (Laminin M Chain or Laminin 12 Subunit Alpha or Laminin 2 Subunit Alpha or Laminin 4 Subunit Alpha or Merosin Heavy Chain or LAMA2) Activator with two drugs in Preclinical. The Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline products include four routes of administration with the top ROA being Intravenous and four key molecule types in the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline products market including Gene Therapy, and Recombinant Protein.
Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) overview
Laminin alpha 2–related muscular dystrophy (LAMA2-MD) is a congenital muscular dystrophy (CMD) that causes muscle weakness and wasting. It is caused by harmful genetic changes in the LAMA2 gene, which is necessary for the proper functioning of skeletal and heart muscles. Symptoms include postnatal hypotonia, weak cry, reduced spontaneous movements, facial weakness, macroglossia, protruding tongue, and progressive limitation of extraocular movements. Diagnosis includes blood tests to measure level of creatine kinase (CK) and EMG for electrical activity in muscles. Treatment options include physical and occupational therapy, speech therapy, and surgery.
For a complete picture of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
